tradingkey.logo
tradingkey.logo
Search

ProQR Therapeutics NV

PRQR
Add to Watchlist
1.720USD
-0.060-3.37%
Close 07-31 16:00ETQuotes delayed by 15 min
228.74MMarket Cap
LossP/E TTM

PRQR Financials

See ProQR Therapeutics NV's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

ProQR Therapeutics NV Earnings Date

Latest Release
May 12, 2026
EPS / Forecast
-0.11/-0.10
Revenue / Forecast
1.73M/4.51M
Period
FY2025 Earnings
Revenue(YoY)
18.82M
-11.29%
EPS(YoY)
-0.47
-40.88%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
-41.72%-0.15
-2.63%-0.10
-10.92%-0.12
-285.89%-0.14
-2.19%-0.10
-30.05%-0.10
-48.33%-0.11
60.99%-0.04
0.56%-0.10
56.55%-0.07
---0.07
---0.09
---0.10
---0.17
---0.72
----
----
----
----
----
Revenue
-55.17%2.39M
0.08%4.10M
-31.49%2.52M
-42.42%3.41M
-2.30%4.22M
-27.89%4.09M
187.76%3.68M
421.03%5.92M
573.54%4.32M
408.38%5.68M
44.36%1.28M
13.06%1.14M
-45.05%641.75K
194.09%1.12M
-11.51%887.02K
81.75%1.00M
899.29%1.17M
75.15%379.77K
373.38%1.00M
-92.43%552.74K
Net Profit
-38.81%-15.71M
9.62%-7.75M
-27.01%-9.53M
-323.44%-10.44M
-26.39%-8.98M
-71.18%-8.57M
-40.62%-7.50M
66.24%-2.47M
13.64%-7.10M
59.15%-5.01M
77.09%-5.34M
45.39%-7.30M
38.56%-8.22M
20.85%-12.26M
-78.82%-23.29M
-0.50%-13.37M
-28.10%-13.39M
-42.74%-15.49M
-17.13%-13.03M
-284.32%-13.31M
Net Margin
-209.65%-658.29%
9.69%-189.14%
-85.38%-377.56%
-635.36%-306.39%
-29.37%-212.59%
-137.39%-209.43%
48.52%-203.67%
93.51%-41.67%
87.06%-164.33%
91.97%-88.22%
---395.62%
---641.75%
---1270.44%
---1098.27%
---1617.03%
----
----
----
----
----
Gross Margin
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
--100.00%
--100.00%
--100.00%
--100.00%
--100.00%
----
----
----
----
----
Debt to assets ratio
42.99%15.89%
38.12%14.16%
-18.55%13.26%
-24.58%12.26%
-28.42%11.11%
-28.38%10.25%
8.72%16.28%
11.74%16.26%
14.49%15.52%
11.60%14.31%
--14.98%
--14.55%
--13.56%
--12.82%
--18.25%
----
----
----
----
----
Revenue
-55.17%2.39M
0.08%4.10M
-31.49%2.52M
-42.42%3.41M
-2.30%4.22M
-27.89%4.09M
187.76%3.68M
421.03%5.92M
573.54%4.32M
408.38%5.68M
44.36%1.28M
13.06%1.14M
-45.05%641.75K
194.09%1.12M
-11.51%887.02K
81.75%1.00M
899.29%1.17M
75.15%379.77K
373.38%1.00M
-92.43%552.74K
Operating profit
-31.93%-16.02M
14.92%-7.90M
-21.13%-9.77M
-218.46%-10.50M
-28.62%-9.63M
-62.23%-9.29M
-16.78%-8.07M
59.04%-3.30M
13.36%-7.49M
50.17%-5.73M
65.11%-6.91M
47.91%-8.05M
46.54%-8.64M
25.87%-11.49M
-57.14%-19.80M
-38.51%-15.46M
-61.19%-16.17M
-61.77%-15.50M
-37.51%-12.60M
-294.49%-11.16M
Net Profit
-38.81%-15.71M
9.62%-7.75M
-27.01%-9.53M
-323.44%-10.44M
-26.39%-8.98M
-71.18%-8.57M
-40.62%-7.50M
66.24%-2.47M
13.64%-7.10M
59.15%-5.01M
77.09%-5.34M
45.39%-7.30M
38.56%-8.22M
20.85%-12.26M
-78.82%-23.29M
-0.50%-13.37M
-28.10%-13.39M
-42.74%-15.49M
-17.13%-13.03M
-284.32%-13.31M
Current assets
-34.14%102.09M
-43.46%86.99M
4.33%96.42M
4.69%106.54M
28.86%138.08M
27.16%153.84M
-25.88%92.41M
-22.40%101.77M
-24.33%107.16M
-21.67%120.99M
19.77%124.69M
-18.57%131.15M
-17.89%141.61M
-19.33%154.46M
-41.20%104.11M
12.17%161.06M
136.70%172.47M
139.29%191.48M
92.13%177.06M
57.52%143.58M
Total current liabilities
8.70%41.15M
-27.55%28.19M
-27.61%28.70M
-23.91%28.37M
-2.04%33.72M
13.74%38.90M
48.75%39.64M
62.25%37.28M
100.58%34.42M
62.01%34.20M
-1.20%26.65M
-15.34%22.98M
-27.64%17.16M
-23.50%21.11M
-22.24%26.97M
119.32%27.14M
125.99%23.71M
167.90%27.60M
220.68%34.69M
36.99%12.37M
Total assets
-31.75%116.24M
-41.67%97.96M
0.78%107.69M
-0.12%117.91M
22.45%151.69M
21.81%167.96M
-24.77%106.85M
-20.23%118.05M
-21.60%123.88M
-19.52%137.88M
16.68%142.03M
-17.35%147.99M
-16.94%158.01M
-18.25%171.32M
-37.68%121.73M
10.28%179.05M
107.66%190.23M
112.28%209.58M
77.26%195.33M
73.64%162.36M
Total liabilities
-11.72%72.11M
-30.64%55.07M
-28.83%58.26M
-29.01%60.48M
-18.30%72.75M
-17.72%79.40M
-14.45%81.87M
-11.70%85.20M
-10.33%89.06M
-9.15%96.49M
67.32%95.69M
4.79%96.49M
10.33%99.31M
10.23%106.21M
-15.03%57.19M
105.47%92.08M
112.16%90.02M
128.41%96.35M
59.88%67.31M
221.66%44.81M
Total equity
-50.20%44.13M
-51.56%42.90M
97.84%49.42M
74.78%57.42M
126.69%78.94M
113.96%88.56M
-46.09%24.98M
-36.21%32.85M
-40.68%34.82M
-36.43%41.39M
-28.20%46.34M
-40.79%51.50M
-41.43%58.70M
-42.49%65.11M
-49.59%64.54M
-26.01%86.97M
103.78%100.22M
100.24%113.23M
88.01%128.02M
47.73%117.54M
Net operating income
26.25%-13.08M
-34.72%-11.60M
-102.36%-10.60M
-70.57%-9.77M
-0.25%-14.07M
-77.17%-8.61M
25.39%-5.24M
39.39%-5.73M
-134.08%-14.04M
70.44%-4.86M
54.27%-7.02M
34.76%-9.45M
312.06%41.18M
-586.27%-16.45M
-120.04%-15.35M
-71.83%-14.49M
-99.19%-19.42M
135.03%3.38M
15.73%-6.97M
4.50%-8.43M
Net investment
23.46%-192.49K
82.21%-456.99K
-100.95%-146.36K
64.59%-86.58K
98.79%-199.52K
-156.24%-2.57M
4982.47%15.47M
8.97%-244.55K
-19971.44%-16.45M
25968.16%4.57M
-28.94%-316.85K
-19.12%-268.64K
64.60%-81.94K
111.81%17.52K
-62.21%-245.73K
-413.14%-225.52K
-772.75%-231.50K
-53.06%-148.33K
31.98%-151.49K
84.83%-43.95K
Net financing
36.44%-356.80K
-100.79%-520.42K
8.29%-384.52K
2.75%-251.18K
-14.59%-445.35K
6697.87%65.82M
-59.64%-419.29K
56.04%-258.29K
-62.98%-388.65K
-107.86%-997.62K
99.40%-262.64K
-68.58%-587.54K
53.71%-238.47K
-47.28%12.69M
-314.28%-43.71M
-100.49%-348.53K
-120.82%-515.18K
14780.98%24.08M
82.40%20.40M
16900.79%70.44M

FAQs

What is the total revenue of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its total revenue reached 18.82M, with a year-on-year change of 21.21M.

What are the current assets of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its current assets were 115.24M, with a year-on-year change of -30.97.

What are the total assets of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its total assets of ProQR Therapeutics NV were 129.78M, with a year-on-year change of -28.80.

What are the total liabilities of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its total liabilities of ProQR Therapeutics NV were 72.95M, with a year-on-year change of -15.33.

What is the total equity of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its total equity of ProQR Therapeutics NV was 56.83M, with a year-on-year change of -40.87.

What is the net operating income of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its net operating income of ProQR Therapeutics NV was -50.01M, with a year-on-year change of -51.22.

What is the net investment of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its net investment of ProQR Therapeutics NV was -1.17M, with a year-on-year change of 73.44.

What is the net financing of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its net financing of ProQR Therapeutics NV was -2.11M, with a year-on-year change of -102.77.

What is the Earnings Per Share (EPS) of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its Earnings Per Share (EPS) was -0.47, with a year-on-year change of -40.88.

What is the net income of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its net income was -48.55M, with a year-on-year change of -61.16.

What is the net margin of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its net profit margin was -258.05, with a year-on-year change of -81.67.

What is the debt-to-asset ratio of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its debt-to-asset ratio was 14.16, with a year-on-year change of 38.12.

What is the Return on Equity (ROE) of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its Return on Equity (ROE) was -61.17, with a year-on-year change of -43.15.

What is the Return on Assets (ROA) of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its Return on Assets (ROA) was -30.05, with a year-on-year change of -65.54.

What is the operating profit of ProQR Therapeutics NV?

According to ProQR Therapeutics NV's FY2025 earnings report, its operating profit was -50.01M, with a year-on-year change of -51.22.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.